Observations on the treatment of rheumatoid disease with penicillamine

Golding, J.; Wilson, Jeffrey; Day, A T

doi:10.1136/pgmj.46.540.599

Cited by 30 publications

(12 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The trial was discontinued if: 1) the rheumatoid arthritis worsened; 2) severe intercurrent illnesses occurred; 3) intolerable toxic effects appeared; or 4) other reasonable causes were noted. Whenever treatment was interrupted before completion, each clinical examination was performed at the day of discontinuance, and the patients were followed up as long as possible.…”

Section: Methodsmentioning

confidence: 99%

Clinical evaluation of D‐penicillamine by multicentric double‐blind comparative study in chronic rheumatoid arthritis

Shiokawa

Horiuchi

Honma

et al. 1977

Arthritis & Rheumatism

View full text Add to dashboard Cite

In order to evaluate clinical efficacy of D-penicillamine (DP) a double-blind study was conducted by the Metalcaptase Research Croup consisting of forty-one rheumatological centers in Japan. A total of 179 patients with rheumatoid arthritis (RA) was divided into two groups; one treated with 5 mg (control group) and the other with 100 mg (drug group) of DP in capsule form. The trial lasted 24 weeks. Global judgment by physicians revealed that improvement was found in 27% in the controls and 65% in the drug group. Adverse reactions occurred in 34% of the controls and 49% of the drug group. Skin rashes, taste disturbances, gastrointestinal upset and proteinuria were frequent in the drug group, but severe or fatal reactions could not be seen in this trial.

show abstract

Section: Methodsmentioning

confidence: 99%

Clinical evaluation of D‐penicillamine by multicentric double‐blind comparative study in chronic rheumatoid arthritis

Shiokawa

Horiuchi

Honma

et al. 1977

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…Agranulocytosis, though rare, is more common in the first year of therapy and is usually reversible on stopping the drug (Golding, Wilson and Day, 1970). Selective red cell aplasia has occurred after prolonged treatment of a patient with Wilson's disease with Dpenicillamine (Gollan et al, 1976).…”

Section: Discussionmentioning

confidence: 99%

Erythro-myeloid aplasia following D-penicillamine treatment in primary biliary cirrhosis

Jones¹,

Corringham²,

Jain³

1978

Postgraduate Medical Journal

View full text Add to dashboard Cite

Summary A woman with primary biliary cirrhosis and a high liver copper concentration was treated with D-penicillamine as a participant in a controlled trial of the drug. After 14 weeks she developed a Pseudomonas septicaemia and was found to have erythro-myeloid aplasia. Similar, but not identical blood dyscrasias have previously been reported as complications of D-penicillamine therapy. She survived after treatment with antibiotics and granulocyte transfusions, and bone marrow function returned to normal.

show abstract

“…Although gold salts (Empire Rheumatism Council, 1960;1961) and more recently, D-pencillamine (Golding et al, 1970;Multicentre Trial Group, 1973), have been shown to have a beneficial effect in the treatment of rheumatoid arthritis, there is still considerable controversy as to the mechanism of their anti-rheumatic action.…”

mentioning

confidence: 99%

Gold and penicillamine: a proposed mode of action in rheumatoid arthritis, based on synovial fluid analysis.

Pritchard¹,

Nuki²

1978

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

SUMMARY Although in common use, there is still controversy as to the way in which gold and penicillamine act in rheumatoid arthritis (RA).In this study, synovial fluids from 4 groups of patients have been compared: (1) RA patients on gold/penicillamine, (2) RA patients on non-steriodal anti-inflammatory drugs (NSAID) only, (3) osteoarthritis patients, and (4) patients with sero-negative arthropathies. The parameters measured were differential agglutination titre (DAT), total haemolytic complement (CH50), total protein, total white cell count, and immunoglobulins. RA patients on gold/penicillamine have lower synovial DAT levels and higher CH50 levels than RA patients on NSAID only, and total and cryoprecipitable IgM levels very close to those found in the sero-negative joint fluids. The non-specific inflammatory parameters, ie, white cell count and total protein are unchanged after gold/penicillamine therapy.In a second study, the serum DATs of patients in total remission after gold/penicillamine were compared with similar patients on NSAID only. The DAT falls significantly in the former group (P<0 *001), but not in the latter suggesting that fall in DAT is a consequence of therapy rather than remission.The parameters altered by gold/penicillamine in the synovial fluid are those that distinguish RA from non-rheumatoid arthropathies suggesting the drug's primary effect is to render the disease sero-negative. The results support the hypothesis that both drugs have a common mode of action based on their active thiol groups, and that the fall in DAT is due to the reduAtion of the antigenicity of the IgG complexes.

show abstract

Observations on the treatment of rheumatoid disease with penicillamine

Cited by 30 publications

References 6 publications

Clinical evaluation of D‐penicillamine by multicentric double‐blind comparative study in chronic rheumatoid arthritis

Clinical evaluation of D‐penicillamine by multicentric double‐blind comparative study in chronic rheumatoid arthritis

Erythro-myeloid aplasia following D-penicillamine treatment in primary biliary cirrhosis

Gold and penicillamine: a proposed mode of action in rheumatoid arthritis, based on synovial fluid analysis.

Contact Info

Product

Resources

About